UBS Maintains Neutral on Insulet, Lowers Price Target to $215
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Matthew Taylor has maintained a Neutral rating on Insulet (NASDAQ:PODD) and lowered the price target from $270 to $215.
September 06, 2023 | 1:56 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
UBS has maintained a Neutral rating on Insulet but lowered the price target from $270 to $215.
The lowering of the price target by UBS from $270 to $215 indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100